Vera Therapeutics Inc (VERA)

NASDAQ
Currency in USD
Disclaimer
13.70
-0.45(-3.18%)
Closed
After Hours
14.38+0.68(+4.96%)
Day's Range
13.6514.24
52 wk Range
5.2021.02
Prev. Close
14.15
Open
14.04
Day's Range
13.65-14.24
52 wk Range
5.2-21.02
Volume
267,617
Average Vol. (3m)
512,598
1-Year Change
-16.82%
Shares Outstanding
44,432,945
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
22.86
Upside +66.86%

People Also Watch

11.18
DYN
-3.29%
19.34
SIBN
+3.70%
21.48
APGE
-1.20%
56.67
PCVX
-0.19%
How do you feel today about VERA?
Vote to see community's results!
or

Vera Therapeutics Inc Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.